1. DOSE‐DENSE CHEMOIMMUNOTHERAPY AND CNS PROPHYLAXIS IN PATIENTS WITH HIGH‐RISK DLBCL: A COMPARISON OF NORDIC CRY‐04 AND CHIC STUDIES. (June 2017) Authors: Leppä, S.; Joergensen, J.; de Nully Brown, P.; Fagerli, U.; Larsen, T.S.; Janes, R.; Mannisto, S.; Munksgaard, L.; Maisenhölder, M.; Vasala, K.; Meyer, P.; Jerkeman, M.; Björkholm, M.; Fluge, Ø.; Jyrkkiö, S.; Pedersen, L.M.; Eriksson, M.; Holte, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C‐III. (1st February 2017) Authors: Ghosh Laskar, M.; Eriksson, M.; Rudling, M.; Angelin, B. Journal: Journal of internal medicine Issue: Volume 281:Number 6(2017) Page Start: 575 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Unique case of cerebrotendinous xanthomatosis revisited: All the mutations responsible for this disease are present in the CYP27A1 gene. (28th November 2017) Authors: Jiao, H.; Olin, M.; Hansson, M.; Eggertsen, G.; Eriksson, M.; Angelin, B.; Björkhem, I. Journal: Journal of internal medicine Issue: Volume 283:Number 6(2018) Page Start: 604 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗